SABCS 2022: Longer-Term Follow-Up Supports Low-Dose Tamoxifen Use in Preventing Breast Cancer Recurrence
Tamoxifen at 5 mg/day for three years significantly lowered recurrence from noninvasive breast cancer at 10 years without excess adverse events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.